Form 4: Sensei COO Anand Parikh Reports Significant Equity Changes Post-Merger

Sensei Biotherapeutics' Chief Operating Officer, Anand Parikh, reported the acquisition of Series B Preferred Stock and employee stock options following the merger with Faeth Holdings Therapeutics.

Summary

• Anand Parikh, Chief Operating Officer and Director of Sensei Biotherapeutics, reported changes in his beneficial ownership of company securities.
• Acquired 809,822 shares of Series B Non-Voting Convertible Preferred Stock on February 17, 2026, which are convertible into 1,000 shares of Sensei Common Stock per preferred share.
• This acquisition was in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. ("HoldCo") as part of a merger agreement dated February 17, 2026, where Sensei Biotherapeutics acquired HoldCo and its subsidiary Faeth Therapeutics, LLC.
• Acquired 92,533 employee stock options on February 17, 2026, with an exercise price of $1.16 and an expiration date of September 14, 2032. These options vest in 48 equal monthly installments starting August 1, 2022, and were received in exchange for Faeth common stock options.
• Acquired 56,673 employee stock options on February 17, 2026, with an exercise price of $1.16 and an expiration date of September 14, 2032. These options are immediately exercisable and were also received in exchange for Faeth common stock options.
• Acquired 1,239,305 employee stock options on February 19, 2026, with an exercise price of $27.22 and an expiration date of February 18, 2036. These options vest 25% on February 19, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the successful completion of a merger and the alignment of a key executive's interests with the combined company's future performance through significant equity holdings.

Positives

• Anand Parikh's increased equity stake, including convertible preferred stock and stock options, aligns his interests with the long-term value creation for Sensei Biotherapeutics shareholders.
• The significant personal investment in the combined entity post-merger demonstrates confidence from a key executive in the company's future prospects.

Risks

• The vesting schedules for the newly acquired stock options introduce future performance incentives but also potential dilution of common stock upon their exercise.
• The Series B Preferred Stock, while initially non-voting, is convertible into common stock, which could impact the company's capital structure and voting dynamics if converted.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company, beyond the specified vesting schedules and expiration dates of the acquired stock options.

Industry Context

StockSavvy.ai notes that this Form 4 reflects the integration of equity compensation and ownership structures following a significant corporate transaction, specifically the acquisition of Faeth Holdings Therapeutics by Sensei Biotherapeutics. Such filings are common post-merger as executive compensation and ownership are realigned with the new combined entity.

Comparison to Industry Standards

• The conversion of Faeth Holdings Therapeutics common stock and options into Sensei Biotherapeutics' Series B Preferred Stock and new options is a standard mechanism for integrating equity ownership in a merger.
• The vesting schedules for the new options (e.g., 25% after one year, then monthly installments) are typical for executive compensation packages in the biotechnology sector, designed to retain talent and align long-term incentives.
• The exercise prices of the new options ($1.16 and $27.22) reflect different valuation points, likely tied to the original Faeth options and new grants post-merger, which is consistent with industry practices for integrating diverse equity instruments.

Corporate Governance

Related Party Transactions

• The transactions are related to the merger, where Anand Parikh, as an executive of the acquiring company, received equity in Sensei Biotherapeutics in exchange for his holdings in the acquired entity (Faeth Holdings Therapeutics/Faeth Therapeutics, LLC). This is a direct consequence of the merger agreement.

Stakeholder Impact

• Shareholders: The conversion feature of the Series B Preferred Stock and the exercise of new stock options could lead to future dilution of common stock. However, the alignment of executive interests post-merger is generally positive.
• Employees: The equity grants to the COO, particularly those exchanged for Faeth options, demonstrate the integration of key personnel from the acquired entity into Sensei's compensation structure.

Next Steps

• Continued vesting of employee stock options according to their respective schedules.
• Potential future conversion of Series B Preferred Stock into Common Stock, subject to certain conditions set forth in the Certificate of Designation.

Key Dates

Recommendation

This Form 4 filing details an insider's equity adjustments following a merger, which is a routine disclosure. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The increased insider ownership is a positive for alignment but doesn't fundamentally alter the investment thesis based solely on this filing. Investors should await further operational updates or financial reports for a more comprehensive assessment.

Keywords

Sensei Biotherapeutics, SNSE, Anand Parikh, Form 4, Insider Trading, Beneficial Ownership, Merger Agreement, Faeth Holdings Therapeutics, Series B Preferred Stock, Stock Options, Equity Compensation, Corporate Governance